Rezulin class action
Executive Summary
Pfizer Rezulin class certification petition denied by Manhattan federal Judge Lewis Kaplan in Sept. 12 decision. Petition consolidated litigation from more than 4,000 Rezulin (troglitazone) patients. The diabetes drug was withdrawn from the market in March 2000, following 90 cases of acute liver damage, including 63 deaths. Class actions in West Virginia and California also have been denied (1"The Pink Sheet" Jan. 7, p. 19)...